Immune Cytolytic Activity as an Indicator of Immune Checkpoint Inhibitors Treatment for Prostate Cancer

Immune checkpoint inhibitors (ICIs) treatment is becoming a new hope for cancer treatment. However, most prostate cancer (PCa) patients do not benefit from it. In order to achieve the accuracy of ICIs treatment in PCa and reduce unnecessary costs for patients, we have analyzed the data from TCGA dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Ze, Tao, Yiran, Lai, Yiming, Wang, Qiong, Li, Zean, Peng, Shirong, Chen, Junxiu, Cai, Wenli, Li, Kaiwen, Huang, Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Bioengineering and Biotechnology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423880/
https://www.ncbi.nlm.nih.gov/pubmed/32850758
http://dx.doi.org/10.3389/fbioe.2020.00930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423880/
https://www.ncbi.nlm.nih.gov/pubmed/32850758
http://dx.doi.org/10.3389/fbioe.2020.00930

Ejemplares similares